Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Vertex Pharmaceuticals
Biotech
EMA clears barrier on road to landmark Vertex-CRISPR approval
Vertex and CRISPR have secured European Medicines Agency validation of the approval application for their CRISPR-Cas9 candidate.
Nick Paul Taylor
Jan 25, 2023 8:20am
Vertex pays Entrada $224M for preclinical rare disease drug
Dec 8, 2022 9:06am
No pain, only gain for Vertex as FDA greenlights phase 3 trial
Jul 22, 2022 10:59am
Vertex puts up $60M to partner on in vivo gene editing program
Jul 21, 2022 9:10am
Vertex buys ViaCyte for $320M, clearing out T1D competition
Jul 11, 2022 11:45am
Vertex's Type 1 diabetes med back on track after FDA hold lifted
Jul 5, 2022 10:23am